Best Drug Delivery Companies in Canada
The 39 best Drug Delivery companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Intellipharmaceutics International.
- Global Drug Delivery Market Up $6.3B in 2020 – Growth Driven by COVID-
- Multiple sclerosis, diabetes and migraine are therapy areas where alte
Ranked: Best Drug Delivery companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Intellipharmaceutics International Specialty company developing generic controlled oral solid dosage drugs | $24M | 81 mo ago | 11 | Isa Odidi Chief Executive Officer | Deadpooled | — | 22 patents Abuse‑deterrent, controlled‑release pharmaceutical formulations reducing overdose risk | — |
| 2 | AmacaThera Developer of an injectable hydrogel platform for a wide range of medical applications | $14M | 66 mo ago | 13 | — | Series A | — | 3 patents Hydrogel-based drug delivery systems for cancer and cannabinoid therapeutics. | 1 partnership |
| 3 | Bionxt Developer of drug formulations and delivery systems for various diseases 37News top 36%Funding top 38%Partners top 40%Patents top 46% All 11 signals ▾Newstop 36% Fundingtop 38% Partnerstop 40% Patentstop 46% Growthtop 47% Talenttop 49% Moatbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 39% Globalbottom 38% News: 9 BI events in 12 mo (of 28 tracked, 7 types) · -36% YoY Funding: Raised $12.6M across 11 rounds · 11 rounds over 4 yrs (2.8/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $13M | 18 mo ago | 25 | Hugh Rogers CEO | Public | Top 50M | 7 patents Formulating psilocin amino‑acid/carbohydrate conjugates and enteric drug delivery systems. | 1 partnership |
| 4 | Ripple Therapeutics Developer of drug delivery system | $12M | 68 mo ago | 32 | Thomas Reeves CEO & President | Series A | — | 63 patents Ophthalmic drug formulations and delivery devices, especially dexamethasone prodrugs. | — |
| 5 | Eternity Healthcare Needle-free injection device | $11M | 142 mo ago | 1 | Hassan Salari Co-Founder | Series A | — | — | — |
| 6 | Lexaria Bioscience Developer of drug delivery technology designed to improve drug absorption | $8M | 35 mo ago | 6 | Chris Bunka CEO & Chairman | Public | Top 10M | — | — |
| 7 | Acasti Developer of drug delivery technology and therapeutics for rare and orphan diseases | $7M | 34 mo ago | 33 | Pierre Lemieux Co-Founder | Series A | — | — | — |
| 8 | IntelGenx Developer of oral thin-film technologies for enhanced drug delivery | $6M | 41 mo ago | 51 | — | Public | Top 50M | 178 patents High‑dose oral thin‑film drug delivery formulations for enhanced bioavailability | — |
| 9 | MedGenesis Therapeutix Therapeutics for neurological diseases | $5M | 175 mo ago | 4 | Erich Mohr Chairman and CEO | Series A | — | 28 patents Intracerebral convection‑enhanced delivery catheters with removable stiffeners and liposomal CNS therapeutics | — |
| 10 | Nanocopoeia US-based nanotechnology company developing drug delivery formulations of existing drugs with increased… | $4M | 205 mo ago | — | Robert Hoerr Chief Scientific Officer & Co-Founder | Funding Raised | — | — | — |
| 11 | Orcosa Developer of cannabinoid-based therapeutics for oncology and neurological disorders | $4M | 20 mo ago | 15 | Bryan Ridall CEO & President | Series B | — | — | — |
| 12 | Sitka Biopharma Canadian, early-stage biopharma developing polymeric nanoparticle-based chemotherapeutics. | $3M | 90 mo ago | 4 | — | Deadpooled | — | — | — |
| 13 | Microdermics Developing a hollow microneedle delivery platform | $1M | 107 mo ago | 1 | — | Series A | — | 25 patents Transdermal microneedle devices for drug delivery and tissue sampling | — |
| 14 | NuVessl Provides its patented nanotechnology encapsulation platform for delivering active ingredients | $945K | 77 mo ago | — | Gijs Koning Managing Director | Seed | — | 33 patents Patents concentrated in health & consumer products | — |
| 15 | Avro Lifesciences Developer of dermal therapies and patches for pediatric use | $150K | 102 mo ago | 19 | — | Seed | — | — | — |
| 16 | PKA SoftTouch Micro-needle injection technology | $111K | 75 mo ago | 2 | — | Seed | — | 31 patents Intradermal and transdermal fluid drug delivery device technologies | — |
| 17 | Entos Pharmaceuticals Provider of nanotech-based drug delivery solutions | $100K | 15 mo ago | 41 | — | Series A | Top 10M | 53 patents Recombinant viral vectors for oncolytic cancer therapy and nucleic‑acid SARS‑CoV‑2 vaccines | 1 partnership |
Top 12 Drug Delivery companies in Canada
#1
Public · Vancouver, British Columbia · founded 2018 · 25 employees$12.6Mraised▾
Developer of drug formulations and delivery systems for various diseases. The company focuses on developing precision transdermal and oral dissolvable drug delivery formulations, rapid, infectious disease, and oral health screening tests, and clinical evaluation of active pharmaceutical ingredients for neurological applications. The company's product include Vektor a drug formulation for efficient and affordable delivery of approved neurological medications.
- Feb 2025Post IPO$1.7M
- Jan 2025Post IPO$138.9K
- Jan 2025Post IPO$620.1K
- Jan 2025Post IPO$288.8K
#2
Series B · Canada · founded 2020 · 15 employees$3.5Mraised▾
Developer of cannabinoid-based therapeutics for oncology and neurological disorders. The company has developed non-opioid analgesics based on rapid infusion technology. It targets CB1 and CB2 receptors to treat traumatic brain injury, neurodegenerative disease, and tumors.
- Dec 2024Series B$7.3M
- Sep 2021Series B$11.3M
#3
Series A · Edmonton, Alberta · founded 2016 · 41 employees$100Kraised▾
Provider of nanotech-based drug delivery solutions. The company is focused on the development of next-generation nucleic acid-based therapies using their proprietary drug delivery system. The system uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi, and CRISPR.
- May 2025Series A$1M
- Feb 2025Grant (prize money)$4M
- Oct 2020Grant (prize money)$5M
- May 2020Seed$100K
#4
Public · Kelowna, British Columbia · founded 2004 · 6 employees$8.3Mraised▾
Developer of drug delivery technology designed to improve drug absorption. The technology enhances the effectiveness of active pharmaceutical ingredients. It formulates therapeutics into oral formats like tablets and suspensions. The technology is available for licensing to improve existing or create new products.
- Oct 2023Post IPO$1.6M
- Dec 2021Post IPO$1.2M
- Jul 2020Post IPO$100K
- May 2020Post IPO$2M
#5
Series A · Laval, Quebec · founded 2008 · 33 employees$7.5Mraised▾
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
#6
Public · Saint laurent, Quebec · founded 2003 · 51 employees$6Mraised▾
Developer of oral thin-film technologies for enhanced drug delivery. It offers products such as proprietary formulation technologies VersaFilmTM, VersaTabTM, and AdVersaTM. It uses technologies IntelGenx enhances the efficacy and deliverability of existing medicines and reintroduces the same in the market as branded products. The VersaFilm technology enables the development of oral thin films that rapidly disintegrate without the need for water, improve buccal and sublingual absorption, and increased bioavailability.
- Mar 2023Convertible Debt$763K
- Sep 2021Post IPO$2.1M
- Oct 2020Post IPO$1.8M
- Oct 2020Post IPO$1.2M
#7
Deadpooled · Toronto, Ontario · founded 1998 · 11 employees$24.4Mraised▾
Intellipharmaceutics International develops controlled-release drug therapies by leveraging its hypermatrix technology, a proprietary multidimensional controlled-release drug delivery platform. The company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, CVS, GIT, diabetes and pain. The Hhpermatrix family of technologies includes intelliFoam, IntelliGITransporter, intelliMatrix, intelliOsmotics, intelliPaste, intelliPellets, intelliShuttle and point of divergence drug delivery system (nPODDDS). The company's products include focalin XR, effexor XR, protonix, glucophage XR, seroquel XR, lamictal XR, keppra XR, pristiq, oleptro, coreg CR, oxyContin and lyrica
- Nov 2019Post IPO$250K
- Mar 2018Post IPO$3.3M
- Mar 2018Post IPO$1.8M
- Oct 2017Post IPO$4M
#8
Series A · Toronto, Ontario · founded 2015 · 13 employees$14.2Mraised▾
Developer of an injectable hydrogel platform for a wide range of medical applications. It can be used for the therapeutic delivery of pharmacological agents for multiple disease areas. The company has also developed a combination product for post-operative pain.
- Feb 2021Series A$8.2M
- Oct 2019Seed$3.6M
- Jan 2019Seed$2.5M
#9
Series A · Toronto, Ontario · founded 2019 · 32 employees$11.6Mraised▾
Ripple Therapeutics develops a drug delivery system. The implants and coatings are made up of the prodrug without a polymeric carrier to control the implant or drug release properties. The lead product (IBE-814 IVT) is a degradable intravitreal dexamethasone prodrug implant targeting different diseases. Other pipelined products are IBE-119 ( intracameral implant) and IBE-1119 ( intravitreal implant).
- Dec 2020Series A$11.6M
#10
Series A · Vancouver, British Columbia · founded 2009 · 1 employees$11Mraised▾
Eternity Healthcare is focussed on discovery, developing and marketing of medical devices. They are currently developing needle-free injection device and pain treatment device. It is a universal injection system that can deliver medication painlessly in both pediatrics and adults. They provide delivery technologies for insulin (diabetes), hCG, hGH, Vit B12, vaccines, anaesthetics, migraine medication and steroids.
- Nov 2014Series A$11M
#11
Funding Raised · St. Paul, Alberta · founded 2001$4Mraised▾
Nanocopoeia is a US-based nanotechnology company developing drug delivery formulations of existing drugs with increased solubility and bioavailability. They have a proprietary technology called ElectroNanoSpray, where Nanoparticle drugs can be produced in a range of sizes (60 nm - 2microns) in one-step. They have multiple university partnerships for further developing their research.
- Jul 2009Grant (prize money)$675K
- Dec 2008Grant (prize money)$570.1K
- Dec 2008Grant (prize money)$570.1K
- Jan 2007Grant (prize money)$675K
#12
Deadpooled · Vancouver, British Columbia · founded 2013 · 4 employees$3.1Mraised▾
Sitka Biopharma is a Canadian, early-stage biopharma developing polymeric nanoparticle-based chemotherapeutics. Its polymeric nanoparticle platform technology Hyperbranched Polyglycerol (HPG) is designed to increase penetration, absorption, and retention of drugs in difficult-to-penetrate tissues. Its drug pipeline includes STK-01 for the Non-muscle invasive bladder cancer (preclinical), for intraperitoneal cancers (preclinical). STK-01 combines the company's HPG nanoparticle platform technology with the established chemotherapeutic docetaxel.
- Feb 2019Seed$1.2M
- Oct 2018Seed$1.9M
- Apr 2016Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Drug Delivery coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Drug Discovery is moving in Canada
A read on the academic research around Drug Discovery — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,145 Canada-affiliated papers.
- University of Toronto153
- Ministry of Education92
- University of British Columbia81
- McGill University74
- Institute of Cancer Research64
- Computational biology10→101
- Chemical space3→52
- Small molecule4→39
- In silico2→33
- Virtual screening4→34
- Computational biology15→78
- Virtual screening1→36
- Docking (animal)2→32
- Drug development3→33
- Small molecule3→27
- Computational biology13→30
- Drug development2→19
- Data science3→11
- In silico1→8
- Chemical space1→7
Where drug discovery is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing drug discovery patents in Canada
Canada drug discovery patent filing is cooling — 31,927 filings from 8,000 assignees (2016–2025), led by UNIV British Columbia, UNIV Health Network, Xenon Pharmaceuticals; annual filings 2885→2717.
- UNIV British Columbia2362
- UNIV Health Network1718
- Xenon Pharmaceuticals1443
- UNIV Alberta822
- NAT RES Council Canada754
- UNIV Montreal722
- Hospital For SICK Children676
- Merck Frosst Canada675
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.